A Randomized, Open-label, Active-controlled Multi-center Study to Assess Safety of Uninterrupted Rivaroxaban vs. Usual Care in Subjects Undergoing Catheter Ablation Therapy for Atrial Fibrillation
Phase of Trial: Phase III
Latest Information Update: 26 Jun 2019
At a glance
- Drugs Rivaroxaban (Primary) ; Vitamin K antagonists
- Indications Stroke; Thrombosis
- Focus Adverse reactions; Registrational
- Acronyms ULTRA-AF; VENTURE-AF
- Sponsors Janssen
- 31 Aug 2018 Biomarkers information updated
- 14 May 2015 According to a Janssen Pharmaceuticals media release, results of this trial build on the promising data observed in a sub analysis of the landmark ROCKET-AF trial (see profile 700020919).
- 14 May 2015 According to a Janssen Pharmaceuticals media release, results from this trial were presented at the Heart Rhythm Society's 36th Annual Scientific Session and published in the European Heart Journal.